Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coramsine
- Development stage
- Discontinued
- Lead developer
- Solbec Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Coramsine (SBP002) is an investigational antineoplastic agent consisting of a 1:1 mixture of the steroidal glycoalkaloids solasonine and solamargine. Derived from the *Solanum linneanum* (Devil's Apple) plant, the drug was developed by Solbec Pharmaceuticals for the treatment of advanced solid tumors, specifically Stage III/IV melanoma and renal cell carcinoma. Its mechanism of action involves the induction of both apoptotic and non-apoptotic programmed cell death in malignant cells, as well as the stimulation of an immune response against tumors. Coramsine received Orphan Drug designation from the U.S. FDA for renal cell carcinoma in 2005 and melanoma in 2006. However, clinical development was halted around 2008 due to financial difficulties and the inability to secure a development partner.
- Brand names
- Coramsine
- Other names
- solasonine + solamargineBEC
02
Targets
RBP (Tumor cell-surface rhamnose-binding protein)Heat shock 70 kDa protein 9-Tumor protein p53 protein-protein interaction interface (Mortalin-p53 PPI)
Beyond the preview
Go deeper on coramsine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coramsine.